Skip to main content
Top
Published in: Clinical Reviews in Bone and Mineral Metabolism 3-4/2005

01-09-2005 | Fibrodysplasia Ossificans Progressiva

The phenotype of fibrodysplasia ossificans progressiva

Authors: Frederick S. Kaplan, MD, David L. Glaser, MD, Eileen M. Shore, PhD, Gregory K. Deirmengian, MD, Rishi Gupta, MD, Patricia Delai, MD, Rolf Morhart, MD, Roger Smith, MD, Martine Le Merrer, MD, John G. Rogers, MD, J. Michael Connor, MD, Joseph A. Kitterman, MD

Published in: Clinical & Translational Metabolism | Issue 3-4/2005

Login to get access
Metadata
Title
The phenotype of fibrodysplasia ossificans progressiva
Authors
Frederick S. Kaplan, MD
David L. Glaser, MD
Eileen M. Shore, PhD
Gregory K. Deirmengian, MD
Rishi Gupta, MD
Patricia Delai, MD
Rolf Morhart, MD
Roger Smith, MD
Martine Le Merrer, MD
John G. Rogers, MD
J. Michael Connor, MD
Joseph A. Kitterman, MD
Publication date
01-09-2005
Publisher
Humana Press
Published in
Clinical & Translational Metabolism / Issue 3-4/2005
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1385/BMM:3:3-4:183

Other articles of this Issue 3-4/2005

Clinical Reviews in Bone and Mineral Metabolism 3-4/2005 Go to the issue

Fibrodysplasia Ossificans Progressiva

Animal models of fibrodysplasia ossificans progressiva

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine